120 research outputs found

    The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids

    Get PDF
    At a population level there is growing evidence for the beneficial effects of dietary flavonoids on health. However there is extensive heterogeneity in the response to increased intake, which is likely mediated via wide inter-individual variability in flavonoid absorption and metabolism. Flavonoids are extensively metabolized by phase I and II- (which occurs predominantly in the gastrointestinal tract and liver) and colonic microbial- metabolism. A number of factors, including age, gender and genotype may impact on these metabolic processes. In addition food composition and flavonoid source is likely to affect bioavailability and emerging data suggest a critical role for the microbiome. This review will focus on the current knowledge for the main sub-classes of flavonoids, including anthocyanins, flavonols, flavan-3-ols and flavanones, where there is growing evidence from prospective studies for beneficial effects on health. Identifying key factors governing metabolism, and understanding if differential capacity to metabolize these bioactive compounds impacts on health outcomes, will help establish how to optimize intakes of flavonoids for health benefits and in specific subgroups. We identify research areas which need to be addressed in order to further understand important determinants of flavonoid bioavailability and metabolism and to advance the knowledge base required to move towards the development of dietary guidelines / recommendations for flavonoids and flavonoid-rich foods

    Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review

    Get PDF
    Apolipoprotein E is a polymorphic and multifunctional protein with numerous roles in lipoprotein metabolism. The three common isoforms apoE2, apoE3 and apoE4 show isoform-specific functional properties including different susceptibilities to diseases. ApoE4 is an accepted risk factor for Alzheimer's disease and cardiovascular disorders. Recently, associations between apoE4 and infectious diseases have been demonstrated. This review summarises how apoE4 may be involved in the infection incidence and associated pathologies of specific infectious diseases, namely hepatitis C, human immunodeficiency virus disease and herpes simplex

    The impact of fatty acid desaturase genotype on fatty acid status and cardiovascular health in adults

    Get PDF
    The aim of this review was to determine the impact of the fatty acid desaturase (FADS) genotype on plasma and tissue concentrations of the long-chain (LC) n-3 PUFA, including EPA and DHA, which are associated with the risk of several diet-related chronic diseases, including CVD. In addition to dietary intakes, which are low for many individuals, tissue EPA and DHA are also influenced by the rate of bioconversion from α-linolenic acid (αLNA). Δ-5 and Δ-6 desaturase enzymes, encoded for by FADS1 and FADS2 genes, are key desaturation enzymes involved in the bioconversion of essential fatty acids (αLNA and linoleic acid (LA)) to longer chained PUFA. In general, carriers of FADS minor alleles tend to have higher habitual plasma and tissue levels of LA and αLNA, and lower levels of arachidonic acid, EPA and also to a lesser extent DHA. In conclusion, available research findings suggest that FADS minor alleles are also associated with reduced inflammation and CVD risk, and that dietary total fat and fatty acid intake have the potential to modify relationships between FADS gene variants and circulating fatty acid levels. However to date, neither the size-effects of FADS variants on fatty acid status, nor the functional SNP in FADS1 and 2 have been identified. Such information could contribute to the refinement and targeting of EPA and DHA recommendations, whereby additional LC n-3 PUFA intakes could be recommended for those carrying FADS minor alleles

    The effect of APOE genotype on Alzheimer’s disease risk is influenced by sex and DHA status

    Get PDF
    An APOE- ε4 genotype is the strongest common genetic determinant of Alzheimer’s disease (AD). The pleiotropic nature of apolipoprotein E, has made elucidation of the aetiological basis difficult to establish which is further complicated by the fact that the penetrance of the APOE- ε4 allele is modulated by sex, age, and nutrition. A greater metabolic consequence of the APOE- ε4 allele is likely to contribute to the fact that two thirds of AD patients are female. A higher tissue status of the marine n-3 fatty acid docosahexaenoic acid (DHA), is associated with a lower AD risk. However, APOE- ε4 carriers appear less sensitive to the neurocognitive benefits, which may be due to defective blood brain barrier transport of DHA exacerbated by ageing and possibly sex. This suggests higher DHA requirements in this large population subgroup. This narrative review will consider the influence of sex and DHA in modulating APOE- ε4 mediated AD risk

    Can nutrition support healthy cognitive ageing and reduce dementia risk?

    Get PDF
    ● Global prevalence of dementia is predicted to almost triple by 2050 ● There are currently no effective drugs to prevent or treat dementia ● Improved eating behaviour holds significant potential to reduce the risk and population prevalence ● Owing to its multifactorial aetiology, multiple dietary components which target several physiological pathways and risk factors simultaneously are needed. Therefore dietary patterns and foods (rather than single dietary components), hold the most promise to meaningfully improve cognition in the medium term ● Randomised controlled trials with robust validated cognitive outcomes or, ideally, change in dementia or mild cognitive impairment incidence are needed in order to support the prospective cohort evidence, establish efficacy and effect size, and inform public health polic

    APOE genotype modifies the plasma oxylipin response to omega-3 polyunsaturated fatty acid supplementation in healthy individuals

    Get PDF
    The omega-3 polyunsaturated fatty acids (n-3 PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), mediate inflammation in large part by affecting pro-inflammatory and anti-inflammatory/pro-resolving oxylipin concentrations. Common gene variants are thought to underlie the large inter-individual variation in oxylipin levels in response to n-3 PUFA supplementation, which in turn is likely to contribute to the overall heterogeneity in response to n-3 PUFA intervention. Given its known role in inflammation and as a modulator of the physiological response to EPA and DHA, here we explore, for the first time, the differential response of plasma hydroxy-, epoxy- and dihydroxy-arachidonic acid, EPA and DHA oxylipins according to apolipoprotein E (APOE) genotype using samples from a dose-response parallel design RCT. Healthy participants were given doses of EPA+DHA equivalent to intakes of 1, 2, and 4 portions of oily fish per week for 12 months. There was no difference in the plasma levels of EPA, DHA or ARA between the wildtype APOE3/E3 and APOE4 carrier groups after 3 or 12 months of n-3 PUFA supplementation. At 12 months, hydroxy EPAs (HEPEs) and hydroxy-DHAs (HDHAs) were higher in APOE4 carriers, with the difference most evident at the highest EPA+DHA intake. A significant APOE *n-3 PUFA dose effect was observed for the CYP-ω hydroxylase products 19-HEPE (p = 0.027) and 20-HEPE (p = 0.011). 8-HEPE, which, along with several other plasma oxylipins, is an activator of peroxisome proliferator activated receptors (PPARs), showed the highest fold change in APOE4 carriers (14-fold) compared to APOE3/E3 (4-fold) (p = 0.014). Low basal plasma EPA levels (EPA 1.22% of total fatty acids). In conclusion, APOE genotype modulated the plasma oxylipin response to increased EPA+DHA intake, with APOE4 carriers presenting with the greatest increases following high dose n-3 PUFA supplementation for 12 months

    Impact of lipoprotein lipase gene polymorphism, S447X, on postprandial triacylglycerol and glucose response to sequential meal ingestion

    Get PDF
    Lipoprotein lipase (LPL) is a key rate-limiting enzyme for the hydrolysis of triacylglycerol (TAG) in chylomicrons and very low-density lipoprotein. Given that postprandial assessment of lipoprotein metabolism may provide a more physiological perspective of disturbances in lipoprotein homeostasis compared to assessment in the fasting state, we have investigated the influence of two commonly studied LPL polymorphisms (rs320, HindIII; rs328, S447X) on postprandial lipaemia, in 261 participants using a standard sequential meal challenge. S447 homozygotes had lower fasting HDL-C (p = 0.015) and a trend for higher fasting TAG (p = 0.057) concentrations relative to the 447X allele carriers. In the postprandial state, there was an association of the S447X polymorphism with postprandial TAG and glucose, where S447 homozygotes had 12% higher TAG area under the curve (AUC) (p = 0.037), 8.4% higher glucose-AUC (p = 0.006) and 22% higher glucose-incremental area under the curve (IAUC) (p = 0.042). A significant gene–gender interaction was observed for fasting TAG (p = 0.004), TAG-AUC (Pinteraction = 0.004) and TAG-IAUC (Pinteraction = 0.016), where associations were only evident in men. In conclusion, our study provides novel findings of an effect of LPL S447X polymorphism on the postprandial glucose and gender-specific impact of the polymorphism on fasting and postprandial TAG concentrations in response to sequential meal challenge in healthy participant
    corecore